Navigation Links
Northwest Biotherapeutics Further Expands Ongoing Brain Cancer Trial
Date:5/25/2011

BETHESDA, Md., May 25, 2011 /PRNewswire/ -- Northwest Biotherapeutics (OTC.BB: NWBO) today announced that it has accelerated the addition of clinical trial sites, exceeding its projections for the doubling of such sites across the U.S. this calendar quarter, for enrollment of new patients into the Company's ongoing 240-patient randomized, double blind, placebo controlled clinical trial of DCVax® immune therapy for Glioblastoma multiforme (GBM), the most lethal form of brain cancer.  

(Logo:  http://photos.prnewswire.com/prnh/20110329/SF73084LOGO)

The Company previously announced 4 clinical sites for new enrollment into the ongoing trial, located in Rochester, Cleveland, Detroit and Minneapolis.  The Company has now added New York City (NYU) and Los Angeles (UCLA).  In addition, the Company is nearing completion on 4 further sites, in New Jersey, Michigan, Texas and Washington.  As a result, the Company expects to have a total of 10 clinical trial sites for new enrollment into its GBM brain cancer trial within this calendar quarter.  This will substantially exceed the Company's projections in regard to the expansion of the clinical trial this quarter.  At least 5 further clinical sites are anticipated to be added in the third quarter of this year, resulting in a total of 15 sites.

"We are gratified to have received such strong interest and cooperation from clinical centers throughout the U.S., and pleased to be ahead of schedule in completing the lengthy and complex institutional processes to make these centers operational for enrollment of additional new patients into our ongoing GBM brain cancer clinical trial," said Dr. Alton Boynton, CEO of NWBT.  

In prior clinical trials of DCVax® immune therapy for GBM brain cancer, the results were striking:  the patients who received DCVax® showed a median survival of 3 years, compared with median survival of only 14.6 months with standard of care today (surgery, radiation and chemotherapy).  In addition, the patients treated with DCVax® did not have recurrence of their tumor for approximately 2 years, on average, as compared with tumor recurrence in just 7 months with standard of care today.  Moreover, the patients treated with DCVax® did not experience any toxic side effects, in stark contrast to chemotherapies.  

About Northwest Biotherapeutics

Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products that treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis.  The Company has a broad platform technology for dendritic cell-based vaccines.  The Company's lead clinical trial is a 240-patient Phase II trial in newly diagnosed Glioblastoma multiforme ("GBM"), the most aggressive and lethal of brain cancer.  The Company also previously received clearance from the FDA for a 612-patient Phase III trial in prostate cancer, and clearance from the FDA for Phase I trials in five other cancers.  The Company has also conducted a Phase I/II trial with DCVax® for recurrent metastatic ovarian cancer.  

For further information about clinical sites and about the Company, please visit the Company's web site at www.nwbio.com.

Disclaimer

Statements made in this news release that are not historical facts, including statements concerning future treatment of patients with GBM using DCVax®-Brain and future clinical trials, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Words such as "expects," "believes," "intends," and similar expressions are intended to identify forward-looking statements.  Actual results may differ materially from those projected in any forward-looking statement.  Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company's ability to raise additional capital, risks related to the Company's ability to enroll patients in its clinical trials and complete the trials on a timely basis, the uncertainty of the clinical trials process, uncertainties about the timely performance of third parties, and whether the Company's products will demonstrate safety and efficacy.  Additional information on these and other factors, including Risk Factors, which could affect the Company's results, is included in its Securities and Exchange Commission ("SEC") filings.  Finally, there may be other factors not mentioned above or included in the Company's SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement.  You should not place undue reliance on any forward-looking statements.  The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.    


'/>"/>
SOURCE Northwest Biotherapeutics
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Northwest Biotherapeutics Conducting Ovarian Cancer Clinical Trial With DCVax(R)-L at University of Pennsylvania
2. Northwestern Memorial Transplant Program Initiates New Study
3. Northwestern Offers Clinical Research and Regulatory Administration Graduate Certificate Program
4. Northwestern Memorial Study Tests Cancer Drug on Scleroderma Patients
5. Evanston Northwestern Healthcare Researchers Explain Effects of Large-Scale, Universal MRSA Surveillance Program That Supports Expanded Intervention
6. CellCyte Genetics Signs Collaborative Agreement With Northwestern Universitys Feinberg School of Medicine to Perform Disease Model Outcome Study of CellCytes CCG-TH30 Product Candidate
7. New Implant Device Remotely Monitors Heart Failure Patients at Northwestern Memorials Bluhm Cardiovascular Institute
8. Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing
9. Swedish Cancer Institute and Elekta Launch Renewed Partnership Agreement to Continue the Flow of World-Class Technology, Services to Cancer Patients in the Pacific Northwest and Beyond
10. Lung Cancer Patients the Centerpiece for Northwestern Medicine Quality of Care Study
11. Northwestern Memorial Maintains Top Status in Nursing Hospital Renewed for Nurse Magnet®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/10/2017)... Hologic, Inc. (Nasdaq: HOLX ) ... second quarter ended April 1, 2017 .   GAAP ... compared to the prior year period as the sale ... gain, while non-GAAP diluted EPS of $0.50 increased 6.4%.  ... constant currency terms.  Excluding the effects of blood screening ...
(Date:5/10/2017)... 10, 2017 Radiology has become the number ... have also spiraled to the number one ranking as ... than ever before as the most complete and reliable ... with lower back pain an MRI may confirm a ... pain, resulting in entirely different treatment protocols.  In these ...
(Date:5/9/2017)... WASHINGTON , May 9, 2017  Demonstrating ... the board of directors for the Pharmaceutical Research ... criteria for membership. Biopharmaceutical companies will now have ... in order to be eligible to join PhRMA. ... criteria, the board is sending a clear message ...
Breaking Medicine Technology:
(Date:5/26/2017)... ... , ... Rob Lowe acts as host and helps educate and inform the ... in American. Viewers can reconnect with America as it explores some of the best ... have looked for an inventive new place for a family vacation, and have discovered ...
(Date:5/26/2017)... ... ... the Garden of Eden”: retells the stories of three Bible figures in modern terms. ... Colt, mother, trader, horse farmer, artist and a former GM journeyman. Born in 1953 ... they moved to Dayton, Ohio, where Penny graduated high school. At sixteen, she toured ...
(Date:5/24/2017)... ... 2017 , ... Dr. Alan I. Benvenisty, MD is dual board certified in ... known for his distinguished expertise and experience in the diagnosis and treatment of vascular ... treating renovascular disease and aortic aneurysm . He is known for his minimally ...
(Date:5/24/2017)... ... 2017 , ... Patients who want to receive cosmetic dentistry procedures such as ... Bedich for a consultation, with or without a referral. Dr. Bedich enjoys improving the ... , Dr. Bedich offers a variety of cosmetic dentistry services at his practice ...
(Date:5/24/2017)... Lehi, Utah (PRWEB) , ... May 24, 2017 , ... ... “Super Sick Kids: The Surprising Truth about Pediatric Septic Shock” hosted by the Journal ... 31, 2017, at 2 p.m. Eastern time, will be presented by Captain Rommie Duckworth, ...
Breaking Medicine News(10 mins):